top of page

Pipeline

Designation

Pre-Clinical Trials

Phase 3

Alzheimer's

Cancer

Development

Phase 2

Phase 1

KCNT1

Alzheimer's 

mRNA combined with lipid nanoparticle technology allows for the insertion of any protein back into individuals missing particular important proteins. In the case of Alzheimer's, as your body ages you cease to produce proteins which refold misfolded proteins. These misfolded proteins, if left unchecked, will form the toxic protein aggregates that cause Alzheimer's related deaths. Our patented technology allows us to reinsert these lost proteins back into individuals afflicted by Alzheimers.

c51f9bf7105dbf5a024f75e4caac1f07.png
bottom of page